 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | AMG 553 / Amgen
Enrollment change, Trial withdrawal, CAR T-Cell Therapy: Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML (clinicaltrials.gov) - Jun 12, 2023
P1, N=0, Withdrawn, Sponsor: Amgen
N=40 --> 0 | Not yet recruiting --> Withdrawn
- | AMG 553 / Amgen
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML (clinicaltrials.gov) - Dec 23, 2021
P1, N=40, Not yet recruiting, Sponsor: Amgen
N=40 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Aug 2029 --> Aug 2030 | Trial primary completion date: Aug 2029 --> Aug 2030
- || AMG 553 / Amgen
Clinical, Journal, CAR T-Cell Therapy, IO biomarker: Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor (CAR) T-cell Therapy for the Treatment of Acute Myeloid Leukemia. (Pubmed Central) - Jul 23, 2021
Potential AMG 553-induced cytotoxicity was assessed against a wide range of normal human primary cells and cell lines; cytotoxicity was observed against FLT3-positive AML cell lines and a percentage of primary bone marrow CD34+ cells. In conclusion, the nonclinical safety data suggest that AMG 553 can target FLT3 protein on AML cells while only affecting a percentage of normal hematopoietic stem and progenitor cells, supporting clinical development.
- | AMG 553 / Amgen
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML (clinicaltrials.gov) - Dec 24, 2020
P1, N=40, Not yet recruiting, Sponsor: Amgen
In conclusion, the nonclinical safety data suggest that AMG 553 can target FLT3 protein on AML cells while only affecting a percentage of normal hematopoietic stem and progenitor cells, supporting clinical development. Trial completion date: May 2029 --> Aug 2029 | Trial primary completion date: May 2029 --> Aug 2029
- | AMG 553 / Amgen
Trial completion date, Trial initiation date, Trial primary completion date, CAR T-Cell Therapy: Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML (clinicaltrials.gov) - Aug 19, 2019
P1, N=40, Not yet recruiting, Sponsor: Amgen
Trial completion date: May 2029 --> Aug 2029 | Trial primary completion date: May 2029 --> Aug 2029 Trial completion date: Dec 2026 --> May 2029 | Initiation date: Sep 2019 --> Dec 2021 | Trial primary completion date: Dec 2026 --> May 2029
- || AMG 553 / Amgen
Trial initiation date, Trial primary completion date, CAR T-Cell Therapy: Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML (clinicaltrials.gov) - Jun 23, 2019
P1, N=40, Not yet recruiting, Sponsor: Amgen
Trial completion date: Dec 2026 --> May 2029 | Initiation date: Sep 2019 --> Dec 2021 | Trial primary completion date: Dec 2026 --> May 2029 Initiation date: Jun 2019 --> Sep 2019 | Trial primary completion date: Nov 2021 --> Dec 2026
- | AMG 553 / Amgen
Trial completion date, CAR T-Cell Therapy: Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML (clinicaltrials.gov) - May 12, 2019
P1, N=40, Not yet recruiting, Sponsor: Amgen
Initiation date: Jun 2019 --> Sep 2019 | Trial primary completion date: Nov 2021 --> Dec 2026 Trial completion date: Nov 2021 --> Nov 2026
- || AMG 553 / Amgen
New P1 trial, CAR T-Cell Therapy: Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML (clinicaltrials.gov) - Apr 3, 2019
P1, N=40, Not yet recruiting, Sponsor: Amgen